Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial

Document Details

Document Type
Pub Defense Publication
Publication Date
Jul 01, 2018
Source ID
10.1016/s2352-3018(18)30071-7

Entities

People

  • Brodie Daniels
  • Carlos A. Diazgranados
  • Carter Bentley
  • Chenchen Yu
  • Craig Innes
  • Daryl E. Morris
  • David C. Montefiori
  • Fatima Laher
  • Georgia D. Tomaras
  • Glenda Gray
  • James G. Kublin
  • Julie McElrath
  • Kathryn Mngadi
  • Kristen W Cohen
  • Lawrence Corey
  • Linda-Gail Bekker
  • Lynn Morris
  • Marcella Sarzotti-kelsoe
  • Marguerite Koutsoukos
  • Mary Allen
  • Merlin L Robb
  • Michael N Pensiero
  • Mookho Malahleha
  • Nelson Michael
  • Nicole Frahm
  • Nicole Grunenberg
  • Niranjan Kanesa-thasan
  • Nonhlanhla N Mkhize
  • Peter B Gilbert
  • Sanjay Phogat
  • Shannon Grant
  • Susan W Barnett
  • Vijay L Mehra
  • Zoe Moodie

Organizations

  • Fred Hutchinson Cancer Center
  • Gates Foundation
  • National Institute of Allergy and Infectious Diseases
  • Sanofi Pasteur
  • United States Army
  • United States Public Health Service

Tags

Technology Areas

  • Biotechnology